Company profile
HOME | pHion Therapeutics | Belfast
pHion Therapeutics Limited strives to pioneer therapeutic vaccines and improve the landscape of AAV manufacture
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
2.17B(NI) | Transaction MzQ0MzUzNDY4MWFkaXF6a2N4 | Paper/PDF filed
Published 19 Nov 2024 01:59
AD01 | Transaction MzQzNjk5MDYyNmFkaXF6a2N4 | Paper/PDF filed
Published 03 Oct 2024 06:45
2.12B(NI) | Transaction MzQzNjk4OTQxMmFkaXF6a2N4 | Paper/PDF filed
Published 26 Sep 2024 06:41
TM01 | Transaction MzQzNTk4OTEzNWFkaXF6a2N4
Published 16 Sep 2024 10:26
Last confirmation statement made up date
Next accounts due date
Last accounts made up date
Company registered at Companies House
pHion Therapeutics develops a formulation that can be used to increase the efficiency of drug development through the use of peptides which speed up the process.
pHion Therapeutics is a therapeutic vaccine development company, utilising its patented peptide based drug delivery system, RALA, which when combined with nucleic acids, generates a uniquely potent therapeutic response without provoking an innate immune response. pHion's therapeutic vaccine programme is focused on viral infections as it evokes a strong interferon gamma response. We believe that the RALA vaccine technology marks the advent of a new generation of therapeutic vaccines that could clear infectious diseases on a global scale. In addition to therapeutic vaccines, RALA possesses unique traits that will offer significant value in both oncology (tumour specific delivery) and in ex vivo gene therapy (nanoparticle formulation for AAV manufacture) applications.
N/A
1 Aug 2023 to 31 Jul 2025
mRNA vaccines have the potential to transform healthcare interventions as evidenced by the approval of 2 products in the last 2 years for Covid-19\. The mRNA codes for an antigen for a disease that can either be administered to healthy patients to prevent infective diseases or can treat diseases such as cancer. Vaccines that prevent disease are typically ...
1 Jun 2023 to 31 May 2025
Prostate cancer (PCa) accounts for 7.3% (1.4 Million) of all cancers worldwide and ~20% become Castrate Resistant Prostate Cancer (CRPC) which is highly aggressive. In the UK the incidence of PCa accounts for 27.8% of all new cancer cases in males. The 5-year survival rates are only 28.9% when metastases arise in CRPC. The incidence in the UK is set to ri...
1 Apr 2022 to 31 Mar 2023
The Crimean-Congo Haemorrhagic Fever (CCHF) is transmitted to humans via infected ticks and through animal reservoirs that carry the virus. CCHF is also transmitted to humans through close contact and bodily fluids and has a fatality rate of 10-40%. CCHF is restricted to primarily warmer countries so any vaccine needs to withstand extreme temperatures. Th...
1 Nov 2021 to 30 Apr 2023
Epithelial ovarian cancer accounts for 90% of all ovarian cancer cases and of these \>50% are the High Grade Serious Carcinomas (HGSC) which is highly aggressive. With no symptoms, most patients are diagnosed at stage 3 or 4 where the 5-year survival rates are only 15%. Given that worldwide, there are 600,000 women living within 5 years with ovarian cance...
1 Apr 2021 to 31 Mar 2022
1 Jan 2021 to 30 Jun 2022
As infections with SARS-CoV-2 continue to rise with associated healthcare and economic implications, there is a race on to develop a vaccine to prevent the disease. RNA vaccines are designed to encode the genetic sequences of antigens of a disease, in this instance SARS-CoV-2 and evoke an appropriate immune response. There are several pipeline mRNA vaccin...
1 Oct 2020 to 30 Sep 2021
RNAi therapeutics have the potential to transform healthcare interventions as evidenced by the approval of 2 products in the last 2 years for life threatening diseases. RNAi therapy is designed to transiently reduce a defective gene for therapeutic purposes. It is a rapidly growing market with 109 RNAi based therapeutics in clinical trials (July 2018) \[W...
1 Jun 2020 to 28 Feb 2021
no public description
1 Jun 2020 to 31 Mar 2021
RNAi therapeutics have the potential to transform healthcare interventions as evidenced by the approval of 2 products in the last 2 years for life threatening diseases. RNAi therapy is designed to transiently reduce a defective gene for therapeutic purposes. It is a rapidly growing market with 109 RNAi based therapeutics in clinical trials (July 2018) \[T...
1 Feb 2020 to 31 Jul 2021
Advancements in the development of genome editing technologies have significantly improved our ability to make precise changes to the DNA of eukaryotic cells, with the potential to truly transform healthcare interventions from the targeting of faulty genomes of cancer cells through to correcting genetic errors of inherited disorders. Despite this potentia...
1 Sep 2019 to 30 Jun 2021
Infection with the human papilloma virus (HPV) leads to genital warts, pre-cancerous lesions and cancer. HPV is the most common sexually transmitted disease, yet all current vaccines are designed to prevent the disease and there is no effective treatment for those currently infected. Given that worldwide there are 200 million currently infected with HPV t...
5 Jun 2019 to 5 Mar 2022
Tumour Targeted Small Molecule Therapeutic (RALgem)
